TP53 and cancer: Recent studies have demonstrated that XI-011 effectively binds to the oncogenic driver heterogeneous nuclear ribonucleoprotein A2B1 and disrupts the heterogeneous nuclear ribonucleoprotein A2B1/MDM4 promoter and untranslated region interaction, thereby activating and stabilizing p53, and inhibiting cancer cell growth [24].